Glenmark Pharmaceuticals Ltd. Announces Unaudited Standalone and Consolidated Earnings Results for the Third Quarter and Nine Months Ended December 31, 2012
January 29, 2013 at 08:05 am EST
Share
Glenmark Pharmaceuticals Ltd. announced unaudited standalone and consolidated earnings results for the third quarter and nine months ended December 31, 2012. On standalone basis, for the quarter, the company reported net sales/income from operations (net of excise duty) of INR 5,348.91 million against INR 3,968.80 million a year ago. Profit from operations before other income, finance costs & exceptional items was INR 1,033.54 million against INR 144.75 million a year ago. Profit from ordinary activities before tax was INR 1,054.37 million against INR 159.56 million a year ago. Net Profit for the period was INR 1,090.36 million or INR 4.02 per diluted share against INR 461.18 million or INR 0.49 per diluted share a year ago.
For the nine months, the company reported net sales/income from operations (net of excise duty) of INR 14,511.52 million against INR 10,966.14 million a year ago. Profit from operations before other income, finance costs & exceptional items was INR 2,556.89 million against INR 1,499.49 million a year ago. Profit from ordinary activities before tax was INR 3,079.92 million against INR 1,429.50 million a year ago. Net Profit for the period was INR 3,011.88 million or INR 11.12 per diluted share against INR 1,170.66 million or INR 4.32 per diluted share a year ago.
On consolidated basis, for the quarter, the company reported net sales/income from operations (net of excise duty) of INR 13,812.59 million against INR 10,310.86 million a year ago. Profit from operations before other income, finance costs & exceptional items was INR 2,845.23 million against INR 797.16 75 million a year ago. Profit from ordinary activities before tax was 2,496.82 million against INR 545.29 million a year ago. Net Profit for the period was INR 2,130.48 million or INR 7.86 per diluted share against INR 131.41 million or INR 1.66 per diluted share a year ago.
For the nine months, the company reported net sales/income from operations (net of excise duty) of INR 36,768.57 million against INR 29,547.87 million a year ago. Profit from operations before other income, finance costs & exceptional items was INR 6,614.10 million against INR 5,510.62 million a year ago. Profit from ordinary activities before tax was INR 5,593.15 million against INR 3,285.86 million a year ago. Net Profit for the period was INR 4,531.65 million or INR 16.53 per diluted share against INR 3,120.81 million or INR 11.46 per diluted share a year ago.
Glenmark Pharmaceuticals Limited is an India-based global pharmaceutical company. The Company is focused on building a global formulation business with branded, generics and over the counter (OTC) segments in the therapy areas of dermatology, respiratory and oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. Its product portfolio includes topical products, liquids, respiratory MDI/DPI, complex injectables and biologics, and oral solids. The Company has a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand, Tiogiva in the United Kingdom and Tavulus in Spain, for the treatment of chronic obstructive pulmonary disease. Ryaltris, the Company's first branded specialty product globally, is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis.
Glenmark Pharmaceuticals Ltd. Announces Unaudited Standalone and Consolidated Earnings Results for the Third Quarter and Nine Months Ended December 31, 2012